{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:01:50Z","timestamp":1790002910796,"version":"4.0.1"},"reference-count":45,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"unspecified","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72342015"],"award-info":[{"award-number":["72342015"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjph"],"accepted":{"date-parts":[[2026,8,18]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The global pharmaceutical industry is undergoing profound changes, with countries worldwide actively investing in innovation ecosystems. In China, innovation has been incentivised through policies aimed at regulatory modernisation, value-based reimbursement and health system integration. In particular, expedited regulatory pathways and inclusion of innovative drugs into the National Reimbursement Drug List (NRDL) through value-based pricing were key approaches adopted by Chinese health authorities. To describe developments under these policies, we map the regulatory approval, reimbursement and postmarketing evidence of class 1 novel drugs across three critical phases: regulatory pathways, value-based reimbursement price negotiation and real-world clinical evidence generation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A mixed-methods approach comprising a cross-sectional study and a literature review was used to aggregate the evidence. We first identified the innovative drugs classified as \u2018class 1 novel drugs\u2019 by the National Medical Products Administration from 2018 to 2023. Second, we collected and analysed evidence of class 1 novel drugs, including timelines of market access and NRDL inclusion, price reduction before and after reimbursement and clinical evidence updates from market access to postmarketing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>95 class 1 novel drugs were identified as being included in the NRDL, with the median regulatory-to-reimbursement interval shortened by more than 50%, from a median of 15 to 7 months. The median price reduction after the value-based pricing was 63%. Furthermore, compared with included drugs\u2019 real-world studies (RWS), clinical trials remained the backbone of evidentiary standards for regulatory approval and reimbursement decisions as they demonstrated superior methodological robustness compared with RWS, which often had limitations related to small sample sizes and inconsistent endpoint definitions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>By linking regulatory approval, reimbursement and postmarketing evidence for China\u2019s class 1 novel drugs, this study provides an integrated evidence base to inform policy discussions on balancing innovation incentives, affordability and evidence generation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjph-2025-004789","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:10:50Z","timestamp":1789999850000},"page":"e004789","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Regulatory approval, reimbursement and postmarketing evidence of class 1 novel drugs in China, 2018\u20132023: an observational study"],"prefix":"10.1136","volume":"4","author":[{"given":"Xin","family":"Gao","sequence":"first","affiliation":[{"name":"China National Health Development Research Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[{"name":"China National Health Development Research Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Yu","sequence":"additional","affiliation":[{"name":"Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Ling","family":"Wang","sequence":"additional","affiliation":[{"name":"China National Health Development Research Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Lu","family":"Zhang","sequence":"additional","affiliation":[{"name":"China National Health Development Research Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Meng","family":"Wang","sequence":"additional","affiliation":[{"name":"China National Health Development Research Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-Yi","family":"Xiao","sequence":"additional","affiliation":[{"name":"China National Health Development Research Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-sha","family":"Lin","sequence":"additional","affiliation":[{"name":"China National Health Development Research Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-fei","family":"Gu","sequence":"additional","affiliation":[{"name":"China National Health Development Research Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhao","sequence":"additional","affiliation":[{"name":"China National Health Development Research Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-zheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"China National Health Development Research Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0387-4550","authenticated-orcid":false,"given":"Thomas","family":"Butt","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yao","sequence":"additional","affiliation":[{"name":"Nanyang Technological University, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4739-8442","authenticated-orcid":false,"given":"Xue","family":"Li","sequence":"additional","affiliation":[{"name":"China National Health Development Research Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4256-7228","authenticated-orcid":false,"given":"Wu-Dong","family":"Guo","sequence":"additional","affiliation":[{"name":"China National Health Development Research Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"2026092107100930000_4.3.e004789.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3744"},{"key":"2026092107100930000_4.3.e004789.2","first-page":"4235","article-title":"Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019","volume":"16","year":"2019","journal-title":"Nat Commun"},{"key":"2026092107100930000_4.3.e004789.3","first-page":"e4","article-title":"Toward a definition of pharmaceutical innovation","volume":"2","author":"Morgan","year":"2008","journal-title":"Open Med"},{"key":"2026092107100930000_4.3.e004789.4","first-page":"53","article-title":"Assessing Definitions and Incentives Adopted for Innovation for Pharmaceutical Products in Five High-Income Countries: A Systematic Literature Review","volume":"37","author":"Wakutsu","year":"2023","journal-title":"Pharmaceut Med"},{"key":"2026092107100930000_4.3.e004789.5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1017\/S0266462318000259","article-title":"Defining innovation with respect to new medicines: A systematic review from a payer perspective","volume":"34","author":"de Sol\u00e0-Morales","year":"2018","journal-title":"Int J Technol Assess Health Care"},{"key":"2026092107100930000_4.3.e004789.6","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3715"},{"key":"2026092107100930000_4.3.e004789.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2011.08.055","article-title":"HT2 Value Based Pricing: One Threshold too Far for the United Kingdom","volume":"14","author":"Roberts","year":"2011","journal-title":"Value in Health"},{"key":"2026092107100930000_4.3.e004789.8","unstructured":"The United States Food and Drug Administration . Novel drug approvals at FDA. 2024. Available: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/novel-drug-approvals-fda [Accessed 4 Aug 2025]."},{"key":"2026092107100930000_4.3.e004789.9","doi-asserted-by":"crossref","DOI":"10.1017\/S026646232300048X","article-title":"Do France, Germany, and Italy agree on the added therapeutic value of medicines?","volume":"39","author":"Casilli","year":"2023","journal-title":"Int J Technol Assess Health Care"},{"key":"2026092107100930000_4.3.e004789.10","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.healthpol.2018.08.009","article-title":"Underuse of innovative medicines in Germany: A justification for government intervention?","volume":"122","author":"Gandjour","year":"2018","journal-title":"Health Policy"},{"key":"2026092107100930000_4.3.e004789.11","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/d41573-021-00080-0","article-title":"Characteristics of expedited programmes for cancer drug approval in China","volume":"20","author":"Li","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2026092107100930000_4.3.e004789.12","doi-asserted-by":"crossref","unstructured":"Tian Y , Liu X , Liu X , et al . Confirmatory Trials for Drugs Granted Conditional Approval by the Chinese National Medical Products Administration. JAMA Health Forum 2024;5.","DOI":"10.1001\/jamahealthforum.2024.4601"},{"key":"2026092107100930000_4.3.e004789.13","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.4750","article-title":"Expedited Approval of Urgently Needed Drugs in China","volume":"6","author":"Wei","year":"2025","journal-title":"JAMA Health Forum"},{"key":"2026092107100930000_4.3.e004789.14","doi-asserted-by":"crossref","DOI":"10.1186\/s12939-025-02390-w","article-title":"Impacts of National Reimbursement Drug Price Negotiation on drug accessibility, utilization, and cost in China: a systematic review","volume":"24","author":"Zhu","year":"2025","journal-title":"Int J Equity Health"},{"key":"2026092107100930000_4.3.e004789.15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41571-023-00728-3","article-title":"Newly approved cancer drugs in China - innovation and clinical benefit","volume":"20","author":"Zhang","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2026092107100930000_4.3.e004789.16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.25973","article-title":"Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020","volume":"5","author":"Zhang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026092107100930000_4.3.e004789.17","unstructured":"National Medical Products Administration . Provisions for drug registration. 2020. Available: https:\/\/sjfg.samr.gov.cn\/law\/file\/pdf\/3235243\/1663496603982.pdf [Accessed 24 Jun 2025]."},{"key":"2026092107100930000_4.3.e004789.18","unstructured":"National Medical Products Administration . NMPA issues requirements for registration classification and application dossiers of chemical drugs. 2020. Available: https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20200630180301525.html [Accessed 4 Aug 2025]."},{"key":"2026092107100930000_4.3.e004789.19","doi-asserted-by":"crossref","first-page":"2327099","DOI":"10.1080\/23288604.2024.2327099","article-title":"Health Technology Assessment in China\u2019s Health Care Sector: Development and Applications","volume":"9","author":"Guo","year":"2023","journal-title":"Health Syst Reform"},{"key":"2026092107100930000_4.3.e004789.20","unstructured":"National Healthcare Security Administration MoF, Ministry of Human Resources and Social Security, National Health Commission . Notice on carrying out the 2018 basic medical insurance for urban and rural residents. 2018. Available: https:\/\/www.nhsa.gov.cn\/art\/2018\/8\/14\/art_37_316.html [Accessed 24 Jun 2025]."},{"key":"2026092107100930000_4.3.e004789.21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamasurg.2021.0546","article-title":"PRISMA Reporting Guidelines for Meta-analyses and Systematic Reviews","volume":"156","author":"Arya","year":"2021","journal-title":"JAMA Surg"},{"key":"2026092107100930000_4.3.e004789.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"2026092107100930000_4.3.e004789.23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/d41573-020-00195-w","article-title":"Trends in oncology drug innovation in China","volume":"20","author":"Li","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2026092107100930000_4.3.e004789.24","unstructured":"National Healthcare Security Administration . National basic medical insurance, work injury insurance, and maternity insurance drug list. 2023. Available: https:\/\/www.nhsa.gov.cn\/art\/2023\/12\/13\/art_104_11673.html [Accessed 24 Aug 2025]."},{"key":"2026092107100930000_4.3.e004789.25","doi-asserted-by":"crossref","unstructured":"Kim M-G , Im Y-J , Lee J-H , et al . n.d. Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study. Front Med 9:1076356. doi:10.3389\/fmed.2022.1076356","DOI":"10.3389\/fmed.2022.1076356"},{"key":"2026092107100930000_4.3.e004789.26","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.19883"},{"key":"2026092107100930000_4.3.e004789.27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/cpt.2988","article-title":"Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective","volume":"114","author":"Zhu","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"2026092107100930000_4.3.e004789.28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2023.10.060","article-title":"A multicenter real-world analysis of risk factors, therapeutics, and outcomes of patients with metastatic basal cell carcinoma","volume":"90","author":"Groover","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026092107100930000_4.3.e004789.29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40263-021-00815-y","article-title":"Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis","volume":"35","author":"Lin","year":"2021","journal-title":"CNS Drugs"},{"key":"2026092107100930000_4.3.e004789.30","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/d41573-024-00120-5","article-title":"Chinese innovative drug R&D trends in 2024","volume":"23","author":"Chen","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2026092107100930000_4.3.e004789.31","unstructured":"The United States Food and Drug Administration . New drug therapy approvals. 2023. Available: https:\/\/www.fda.gov\/media\/175253\/download?attachment [Accessed 23 Aug 2025]."},{"key":"2026092107100930000_4.3.e004789.32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-53554-7","article-title":"Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980-2022","volume":"14","author":"Seoane-Vazquez","year":"2024","journal-title":"Sci Rep"},{"key":"2026092107100930000_4.3.e004789.33","unstructured":"Centre for Innovation in Regulatory Science . Analysis of new drug approvals by six major authorities (2014-2023): evolving regulatory landscape and facilitated regulatory pathways. 2025. Available: https:\/\/www.cirsci.org\/publications\/cirs-rd-briefing-101-new-drug-approvals-by-six-major-authorities-2015-2024\/ [Accessed 24 Aug 2025]."},{"key":"2026092107100930000_4.3.e004789.34","unstructured":"IQVIA . Global R&D trends 2026. 2026. Available: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/global-r-and-d-trends-2026 [Accessed 30 Jun 2026]."},{"key":"2026092107100930000_4.3.e004789.35","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.25.2.452"},{"key":"2026092107100930000_4.3.e004789.36","doi-asserted-by":"crossref","unstructured":"Glaus CEG , Serra-Burriel M , Dusetzina SB , et al . Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States. 2011;177:1442\u20134. doi:10.7326\/ANNALS-24-00614","DOI":"10.7326\/ANNALS-24-00614"},{"key":"2026092107100930000_4.3.e004789.37","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.4461","article-title":"Launch and Postlaunch Price Developments of New Drugs in the US, Germany, and Switzerland","volume":"5","author":"Laube","year":"2024","journal-title":"JAMA Health Forum"},{"key":"2026092107100930000_4.3.e004789.38","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41587-023-02096-w","article-title":"Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act","volume":"42","author":"Vogel","year":"2024","journal-title":"Nat Biotechnol"},{"key":"2026092107100930000_4.3.e004789.39","doi-asserted-by":"crossref","DOI":"10.1080\/20016689.2023.2218633","article-title":"Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement","volume":"11","author":"Macabeo","year":"2023","journal-title":"J Mark Access Health Policy"},{"key":"2026092107100930000_4.3.e004789.40","unstructured":"National Healthcare Security Administration . Rules for renewal of negotiated drugs. 2023. Available: https:\/\/www.gov.cn\/zhengce\/\/202308\/content_6897928.htm [Accessed 24 Aug 2025]."},{"key":"2026092107100930000_4.3.e004789.41","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/S1470-2045(23)00592-2","article-title":"Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications","volume":"25","author":"Koole","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026092107100930000_4.3.e004789.42","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j5262","article-title":"Real world evidence: experience and lessons from China","volume":"360","author":"Sun","year":"2018","journal-title":"BMJ"},{"key":"2026092107100930000_4.3.e004789.43","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068911","article-title":"Use of real world data to improve drug coverage decisions in China","volume":"381","author":"Wang","year":"2023","journal-title":"BMJ"},{"key":"2026092107100930000_4.3.e004789.44","doi-asserted-by":"crossref","DOI":"10.1186\/s12962-022-00412-w","article-title":"Use of real-world evidence to support regulatory decisions on medical devices in China and a unique opportunity to gain accelerated approval in \u201cBoao Lecheng Pilot Zone\u201d","volume":"21","author":"Li","year":"2023","journal-title":"Cost Eff Resour Alloc"},{"key":"2026092107100930000_4.3.e004789.45","unstructured":"National Institute for Health and Care Excellence . Real-world evidence framework. 2022. Available: https:\/\/www.nice.org.uk\/corporate\/ecd9\/chapter\/overview [Accessed 24 Jun 2025]."}],"container-title":["BMJ Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjph-2025-004789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:11:01Z","timestamp":1789999861000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjpublichealth.bmj.com\/lookup\/doi\/10.1136\/bmjph-2025-004789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9,21]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjph-2025-004789"],"URL":"https:\/\/doi.org\/10.1136\/bmjph-2025-004789","relation":{},"ISSN":["2753-4294"],"issn-type":[{"value":"2753-4294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}